Valora Therapeutics’ antibody lectin chimeras, or AbLecs, target glyco-immune checkpoints, pathways that modulate cellular communication with the immune system. The startup’s science is based on research from Carolyn Bertozzi, a Stanford professor who was awarded the 2022 Nobel Prize in Chemistry.
The biotech company will have the exclusive option to buy the remainder of the company, while Pionyr's shareholders will be entitled to up to nearly $1.5 billion in option exercise fees and milestone payments.
Medical billing is a tedious administrative task, but outsourcing it may be the key to increased revenue. Explore the top medical billing outsourcing companies and the benefits of partnering with one.
Two drugs - Pfizer and Merck KGaA's Bavencio and AstraZeneca's Imfinzi - saw Phase III trials fail, while anticipated negative results prompted Roche to withdraw Tecentriq from regulatory review.
Data from the Phase III MYSTIC study showed Imfinzi and tremelimumab did not extend survival in first-line NSCLC. AstraZeneca's shares were down on the news.
Immuno-oncology is on a roll, yet many questions remain unanswered. What incites an immune response and where does the future of the field lie?
Checkpoint Pharmaceuticals wants to advance a drug that boosts immune activity to make checkpoint inhibitors work better.
The home care industry is booming. As Baby Boomers age and more families seek in-home solutions for loved ones, demand for home care services is at an all-time high.